Enrich Biosystems

Enrich Biosystems makes TROVO - the all-in-one benchtop instrument for image-based cell screening and retrieval. learn more:

[Enrich Biosystems @EnrichBio]

Free webinar Sept 10!

Dr. Samuel Katz (Yale) on single-cell profiling of TIL products from melanoma patients who progressed on checkpoint inhibitors, what separated the longer survivors from the shorter ones.

10:00 AM EST, live Q&A.

https://t.co/sm0jReLT4p

[Enrich Biosystems @EnrichBio]

@JournalofExper1 B cells in the TIL compartment don't get nearly enough attention. Good paper.

[Enrich Biosystems @EnrichBio]

@utswcancer Congrats to the team, that's a big first.

[Enrich Biosystems @EnrichBio]

@jitcancer Signatures that flag who's going to benefit are the whole ballgame right now. Adding this to the reading pile.

[Enrich Biosystems @EnrichBio]

Free webinar Sept 10!!!!!!!!!

Dr. Samuel Katz (Yale) on single-cell profiling of TIL products from melanoma patients who progressed on checkpoint inhibitors, what separated the longer survivors from the shorter ones.

10:00 AM EST, live Q&A.
https://t.co/hDBPsBrfvr

[Enrich Biosystems @EnrichBio]

Thousands of cocultures in one standard 6-well plate. No microfluidics, no new labware.

Watch what your T cells actually do over days, cytotoxicity, persistence, exhaustion, then pull the winners out alive, transcriptome intact.

Function first. Markers optional.

https://t.co/tL8Y6rLcjM

[Enrich Biosystems @EnrichBio]

@VincentRK Getting an approval from six days ago into a review is the part that matters — most are a year stale by the time they publish. An annually refreshed open-access review probably moves practice more than another set of static guidelines.

[Enrich Biosystems @EnrichBio]

@RahulBanerjeeMD @binaytara @mshadman @KrishPatelMD The regulatory bullet is doing a lot of quiet work there. Distributed manufacturing runs into a framework built around shipping one centralized batch — once every site makes its own, proving comparability between them becomes the real bottleneck.

[Laura Alder, MD @LauraAlderMD]

Honored to present our Tarlatamab data in active brain mets & treatment beyond isolated CNS progression at #SNOASCO2026!

Key findings in 91 pts:
✅ 33% intracranial ORR in ACTIVE, radiation-naïve brain mets
✅ No clear ↑ in severe CRS/ICANS w/ CNS radiation concurrent with tarlatamab
✅ Treatment beyond isolated CNS progression feasible: +4.3 mo median additional time on therapy with local therapy

First report of continuing a BiTE beyond CNS progression in SCLC. Manuscript in process. Strong signal. Prospective validation needed. 🧠🫁

Grateful to the SNO/@ASCO chairs & organizers, Dr Hattangadi-Gluth @JHGLab and Dr Naidoo @DrJNaidoo
@DukeCancer @UNC_Health_Care @DukeHealth @DukeMets

[Enrich Biosystems @EnrichBio]

@DrRishabhOnco The oleclumab arm is the one I'd want re-cut by adenosine signature. Adenosine blockade keeps underdelivering in all-comers designs, and TNBC is heterogeneous enough that an unselected arm this size could dilute a real effect in a subset.

[Enrich Biosystems @EnrichBio]

@sanamloghavi This is the good version of academic Twitter. Paywalls bite hardest on review issues too — reviews are exactly what people outside the subspecialty are trying to read.

[Enrich Biosystems @EnrichBio]

@DrSamuelBHume CAR-M is an interesting one to be leading on — macrophages get into solid tumors in a way CAR-T still struggles with, but you can't expand them the way you expand T cells, so manufacturing is the harder half. Curious what the trial designs look like up close.

[Enrich Biosystems @EnrichBio]

@PTarantinoMD First-line ADC always raises the same question — does putting T-DXd up front cost you the TKI option later or just reorder it. OS will carry a lot of weight here given the ILD burden now lands on a first-line population.

[Enrich Biosystems @EnrichBio]

@LauraAlderMD The concurrent CNS RT safety data is the part I didn't expect — that sequencing question comes up constantly with almost nothing to go on. Curious whether intracranial response tracked with peripheral T cell expansion at all.

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: "Circulating B cell and T cell activation states predict clinical outcomes in melanoma and reveal dynamic immune reinvigoration with checkpoint inhibitor immunotherapy" https://t.co/WFkhuH8z54

[Enrich Biosystems @EnrichBio]

@jitcancer The B cell half is the surprise — CPI biomarker work is so T cell-centric that circulating B states rarely get a look. And catching reinvigoration through serial blood draws is a lot more tractable than serial tumor biopsies.

[Enrich Biosystems @EnrichBio]

@bherzbergmd @JiaJennyLiu Log-kill also assumes the fraction you're killing is the same cells each cycle. If you're enriching a resistant subpopulation instead of depleting it, more treatments buys you less than the math predicts.

[Enrich Biosystems @EnrichBio]

CAR-T cell efficacy isn't a single metric, it's a multifaceted puzzle of killing potential, exhaustion profiles, and proliferation. Because the low-hanging fruit of killing has been picked, the next era of immune engineering requires deep screening capable of isolating the subtle, combinatorial variations that truly optimize construct performance.

#CAR_T #CellEngineering #celltherapy #cancerimmunotherapy

[Enrich Biosystems @EnrichBio]

Full webinar now posted!
https://t.co/oaehl0c9w6

[Enrich Biosystems @EnrichBio]

God she's beautiful